Paclitaxel-Loaded Core–Shell Magnetic Nanoparticles and Cold Atmospheric Plasma Inhibit Non-Small Cell Lung Cancer Growth

Abstract

Nanoparticle-based drug delivery allows effective and sustained delivery of therapeutic agents to solid tumors and has completely changed how cancer is treated. As a new technology for medical applications, cold atmospheric plasma (CAP) shows a great potential in selective cancer treatment. The aim of this work is to develop a new dual cancer treatment approach by integrating CAP with novel paclitaxel (PTX)-loaded nanoparticles for targeting A549 cells. For this purpose, PTX-loaded core-shell magnetic nanoparticles were prepared through coaxial electrospraying, and various characteristics were investigated. Biodegradable poly(lactic- co-glycolic acid) was selected as the polymer shell to encapsulate the anticancer therapeutics. Results demonstrated a uniform size distribution and high drug encapsulation efficiency of the electrosprayed nanoparticles, which had sustained release characteristics and a variety of excellent properties. An in vitro study showed that PTX-loaded nanoparticles and CAP synergistically inhibited the growth of A549 cells more effectively than when each was used individually. We also found that CAP could induce the PTX-loaded nanoparticles in tumor cells to increase the effective drug concentration to a level that might be conducive to reduce drug resistance. Therefore, the integration of PTX-encapsulated nanoparticles and CAP provides a promising tool for the development of a new non-small cell lung cancer treatment strategy.